How I treat elderly patients with myeloma

Blood

Volumn 116, Issue 13, 2010, Pages 2215-2223

  Mehta, Jayesh ^a   Cavo, Michele ^b   Singhal, Seema ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ANTIANEMIC AGENT; BORTEZOMIB; CALCITONIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PLERIXAFLOR; PREDNISONE; PROTON PUMP INHIBITOR; THALIDOMIDE; UNCLASSIFIED DRUG; WARFARIN; ZOLEDRONIC ACID;

ADD ON THERAPY; AGED; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOTHERAPY; COMORBIDITY; CUSHING SYNDROME; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHROCYTE TRANSFUSION; FLUID THERAPY; GASTRITIS; GASTROINTESTINAL DISEASE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INFECTION PREVENTION; INSOMNIA; KIDNEY DYSFUNCTION; KYPHOPLASTY; KYPHOSCOLIOSIS; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; MYELOMA; NEUROPATHY; OPPORTUNISTIC INFECTION; OSTEOPENIA; OVERALL SURVIVAL; PATIENT CARE; PERCUTANEOUS VERTEBROPLASTY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REMISSION; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; ULCER; WEIGHT GAIN;

EID: 77957699967     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-163329     Document Type: Review

References (48)

1. Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant. 2007;40(12):1101-1114. (Pubitemid 350193802)
2. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants multiple myeloma. Blood. 1999;93(1):51-54.
3. Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000;25(5):533-539.
4. Singhal S, Mehta J. Multiple myeloma. Clin J Am Soc Nephrol. 2006;1(6):1322-1330.
5. Singhal S, Stein R, Vickrey E, Mehta J. The serum free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood. 2007;109(8):3611-3612. (Pubitemid 46572562)
6. Durie BGM, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379-398.
7. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009;115(1):229-232.
8. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565-1571.
9. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617. (Pubitemid 36741588)
10. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133- 2142.
11. Dingli D, Gay F, Buadi F, et al. Depth of response with stem cell transplantation and outcome for multiple myeloma in the era of novel agents [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 1228.
12. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218.
13. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 Trial. J Clin Oncol. 2009;27(22):3664-3670.
14. San Miguel J, Schlag R, Khuageva N, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
15. Palumbo A, Dimopoulos MA, Delforge M, et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 613.
16. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112(8):3107-3114.
17. Mateos MV, Oriol A, Martinez J, et al. A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 3.
18. Singhal S, Mehta J. Treatment of relapsed and refractory multiple myeloma. Curr Treat Options Oncol. 2003;4(3):229-237.
19. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
20. Cavo M, Benni M, Ronconi S, et al. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica. 2002;87(9):934-942.
21. Mehta J. Treatment for elderly patients with multiple myeloma. Lancet. 2008;371(9617):983-985.
22. Ludwig H, Hajek R, Tothova E, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2009;113(15):3435-3442.
23. Morgan GJ, Davies FE, Gregory WM, et al. The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 352.
24. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259-2266.
25. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 128.
26. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007;25(28):4459-4465. (Pubitemid 350063804)
27. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009;114(3):518-521.
28. Singhal S, Mehta J. Thalidomide for relapsed or refractory myeloma. In: Chanan-Khan A, ed. Immunomodulating Drugs for the Treatment of Cancer. In preparation.
29. Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med. 2006;354(10):1076-1078.
30. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106(1):35-39. (Pubitemid 40967171)
31. Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26(13):2171-2177.
32. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27(11):1788-1793.
33. Cavo M, Pantani L, Tacchetti P, et al. Thalidomide maintenance in multiple myeloma: certainties and controversies. J Clin Oncol. 2009;27(32):e186-e187.
34. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557-3560.
35. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-3901. (Pubitemid 47477266)
36. Cavo M, Tacchetti P, Patriarca F, et al. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 351.
37. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112(12):4445-4451.
38. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100(9):3063-3067.
39. Singhal S, Mehta J. Lenalidomide in myeloma. Curr Treat Options Oncol. 2007;8(2):154-163.
40. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114(3):600-607. (Pubitemid 32953638)
41. Qazilbash MH, Saliba RM, Hosing C, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007;39(5):279-283.
42. Harousseau JL, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone (VD) versus reduced-dose bortezomib plus thalidomide plus dexametasone (vTD) as induction treatment prior to autologous stem-cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 354.
43. Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 653.
44. Mezzano SA, Barría M, Droguett MA, et al. Tubular NF-κB and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001;60(4):1366-1377. (Pubitemid 32960030)
45. Lee SJ, Richardson PG, Sonneveld P, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 2008;143(4):511-519.
46. Gulbrandsen N, Wisløff F, Brinch L, et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol. 2001;18(1):65-77.
47. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92(9):3131-3136.
48. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23(36):9227-9233. (Pubitemid 46260178)